EyePoint (EYPT) Short term Debt (2022 - 2023)
EyePoint (EYPT) reported Short term Debt of $5.3 million for Q1 2023, down 49.45% on a YoY basis from $10.5 million in Q1 2022, and down 49.45% sequentially from $10.5 million in Q4 2022.
EyePoint (EYPT) Short term Debt (2022 - 2023) Analysis & Trends
EyePoint (EYPT) has 2 years of Short term Debt data on file, last reported at $5.3 million in Q1 2023.
- For the quarter ending Q1 2023, Short term Debt fell 49.45% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2023 stood at $5.3 million (down 49.45% YoY), and the FY2022 full-year result was $10.5 million, changed N/A from the prior year.
- Short term Debt fell to $5.3 million in Q1 2023, from $10.5 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $10.5 million in Q1 2022 to a low of $5.3 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 5.30 Mn |
| Dec 31, 2022 | 10.48 Mn |
| Sep 30, 2022 | 10.48 Mn |
| Jun 30, 2022 | 10.48 Mn |
| Mar 31, 2022 | 10.48 Mn |